Oregon Measures Real-World Results of Regulated Psilocybin Services

A groundbreaking cohort study in Oregon provides real-world safety and mental health data on regulated psilocybin services, offering crucial insights into therapeutic outcomes. The research tracks actual patient experiences and clinical results from Oregon's first legal psilocybin-assisted therapy programs, which began operations in 2023. These findings are significant for understanding the efficacy and safety profile of psilocybin in treating depression, anxiety, and PTSD under clinical supervision. The data helps inform evidence-based policy decisions and demonstrates the importance of regulatory frameworks that prioritize patient safety while enabling therapeutic innovation. This research bridges the gap between preliminary clinical trials and real-world implementation, providing essential information for healthcare providers and policymakers.